Abbott Laboratories ABT
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 920.00M | 928.00M | 1.08B | 1.78B | 1.64B |
| Total Depreciation and Amortization | 1.26B | 1.06B | 803.00M | 792.00M | 791.00M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 137.00M | 168.00M | 317.00M | 178.00M | 120.00M |
| Change in Net Operating Assets | -576.00M | 332.00M | -882.00M | 569.00M | 232.00M |
| Cash from Operations | 1.74B | 2.49B | 1.32B | 3.32B | 2.79B |
| Capital Expenditure | -513.00M | -497.00M | -399.00M | -689.00M | -496.00M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -121.00M | -164.00M | -19.80B | -20.00M | -55.00M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 249.00M | -12.00M | -127.00M | -204.00M | 94.00M |
| Cash from Investing | -385.00M | -673.00M | -20.32B | -913.00M | -457.00M |
| Total Debt Issued | -67.00M | 31.00M | 19.89B | 2.00M | 0.00 |
| Total Debt Repaid | -1.33B | -1.41B | -1.42B | -72.00M | -493.00M |
| Issuance of Common Stock | 100.00M | 3.00M | 116.00M | 5.00M | 69.00M |
| Repurchase of Common Stock | -11.00M | -1.05B | -180.00M | -302.00M | -305.00M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -1.09B | -1.10B | -1.10B | -1.03B | -1.03B |
| Other Financing Activities | -- | -- | -- | 0.00 | 0.00 |
| Cash from Financing | -2.41B | -3.52B | 17.31B | -1.40B | -1.76B |
| Foreign Exchange rate Adjustments | 1.00M | 4.00M | -23.00M | 6.00M | -10.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.05B | -1.70B | -1.72B | 1.01B | 560.00M |